---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066947"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:17:33.112113+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology completes enrollment in Phase 2 onvansertib trial for RAS-mutated mCRC; Q1 cash $79.9M

## Summary
- Completed enrollment in Phase 2 CRDF-004 trial of onvansertib + SoC for first-line RAS-mutated mCRC across 41 U.S. sites.
- Received second USPTO patent (No. 12,263,173) for onvansertib + bev in all bev-naïve mCRC patients, expiring no earlier than 2043.
- Cash and investments $79.9M as of March 31, 2025; projected runway into Q1 2027.
- Q1 2025 operating expenses $14.5M (up from $11.1M YoY); net cash used in ops $12.8M (up from $7.7M YoY).
- Additional CRDF-004 clinical data expected in first half of 2025.

## SEC filing metadata
- accession: 0000950170-25-066947
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000095017025066947/0000950170-25-066947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000095017025066947/crdf-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066947
- JSON: https://secwatch.observer/filing/0000950170-25-066947.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.